In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen |
|
In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant |
|
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening |
|
Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis |
|
Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection |
|
Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals |
|
Insect cells for antibody production: evaluation of an efficient alternative. |
|
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models |
|
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA |
|
Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model |
|
Introductions and early spread of SARS-CoV-2 in the New York City area |
|
Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells |
|
Mapping SARS-CoV-2 antigenic relationships and serological responses |
|
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) |
|
Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines |
|
MHC class II proteins mediate cross-species entry of bat influenza viruses |
|
Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave |
|
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination |
|
Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein |
|
Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study |
|
Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus |
|
Moving from Empirical to Rational Vaccine Design in the 'Omics' Era |
|
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions |
|
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice |
|
The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain |
|
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine |
|
Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model |
|
Novel universal influenza virus vaccine approaches |
|
A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses |
|
NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge |
|
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. |
|
Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination. |
|
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact |
|
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo |
|
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts |
|
Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time? |
|
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses |
|
Pre-existing anti-neuraminidase antibodies are associated with shortened duration of influenza A (H1N1)pdm virus shedding and illness in naturally infected adults |
|
Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients |
|
Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination |
|
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. |
|
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans |
|
Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections |
|
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine |
|
Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies |
|
Purification of infective baculoviruses by monoliths |
|
Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera |
|
The Quest for a Universal Flu Vaccine: Headless HA 2.0. |
|
Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology |
|
Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs |
|
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City |
|
Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity |
|
Robust and specific secretory IgA against SARS-CoV-2 detected in human milk |
|
Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2 |
|
SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike |
|
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation |
|
SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup |
|
SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19 |
|
SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study |
|
SARS-CoV-2 Vaccines: Status Report |
|
Scientific consensus on the COVID-19 pandemic: we need to act now |
|
Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model |
|
Seroconversion in household members of COVID-19 outpatients |
|
Serology assays to manage COVID-19 |
|
Seroprevalence of SARS-CoV-2 among children visiting a hospital during the initial Seattle outbreak |
|
Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza. |
|
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine |
|
Stopping emerging influenza viruses at their origin |
|
Strategies to induce broadly protective antibody responses to viral glycoproteins |
|
Surveillance of European Domestic Pig Populations Identifies an Emerging Reservoir of Potentially Zoonotic Swine Influenza A Viruses |
|
Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. |
|
Symptomatic SARS-CoV-2 infections display specific IgG Fc structures |
|
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses |
|
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development |
|
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection |
|
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals |
|
Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection InVitro and in a Mouse Model. |
|
Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice |
|
Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A Viruses |
|
Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement |
|